Indications for: KEDRAB

Post-exposure prophylaxis of rabies infection, to be given with a full course of rabies vaccine.

Adult Dosage:

Prior to administration, follow recommendations for local treatment of wounds. Administer as soon as possible after exposure; may give up to 7 days after first vaccine dose. 20 IU/kg as single dose with first dose of rabies vaccine. If feasible, infiltrate dose into and around the wound; inj remainder into upper arm deltoid region. Avoid same inj site as rabies vaccine or repeat doses of Kedrab once vaccine treatment is initiated.

Children Dosage:

See full labeling.

KEDRAB Warnings/Precautions:

Do not inj into gluteal region or blood vessel. History of complete pre- or post-exposure vaccination and confirmed adequate rabies titer: not recommended. Discontinue if allergic or anaphylactic reaction occurs; have epinephrine available. History of allergic reactions to human immunoglobulins; monitor. IgA deficiency. Increased risk of thrombosis with acquired or hereditary hypercoagulable states, prolonged immobilization, in-dwelling vascular catheters, older age, estrogen use, a history of venous or arterial thrombosis, cardiovascular risk factors, hyperviscosity syndromes; monitor for ≥24hrs post-injection. Increased risk of hemolysis with non-O blood group types, underlying inflammatory conditions, high cumulative doses of immune globulins. Contains human plasma; monitor for possible viral disease and variant Creutzfeldt-Jakob disease transmission. Pregnancy. Nursing mothers.

KEDRAB Classification:

Immune globulin.

KEDRAB Interactions:

Avoid measles vaccine within 4 months of Kedrab; avoid other live attenuated vaccines within 3 months. May interfere with serologic tests (eg, Coombs’ test).

Adverse Reactions:

Inj site pain, headache, muscle pain, upper respiratory tract infection; anaphylactic shock.

Generic Drug Availability:


How Supplied:

Single-use vial (2mL, 10mL)—1